Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Baer

Showing results (431-440 of 628) with videos related to

Pageof 63
Sort By:
Proceedings of the ... IEEE Conference on Nanotechnology. IEEE Conference on Nanotechnology|June 21, 2014
Testing in EHS: What is the Current Status of Experimentation?Donald R Baer, Ajay S Karakoti, Prabhakaran Munusamy, et al.
Leukemia & Lymphoma|July 25, 2014
A novel TTC40-MSI2 fusion in de novo acute myeloid leukemia with an unbalanced 10;17 translocationReza Saleki, Todd Christensen, Weihua Liu, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Leukemia Research|July 20, 2018
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasmsJ Berdeja, F Palandri, M R Baer, et al.
Nature Genetics|December 1, 1996
Identification of a RING protein that can interact in vivo with the BRCA1 gene productL C Wu, Z W Wang, J T Tsan, et al.
International Journal of Molecular Epidemiology and Genetics|September 28, 2011
XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemiaNataliya Kuptsova-Clarkson, Christine B Ambrosone, Joli Weiss, et al.
Cancer|April 2, 2011
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaMeir Wetzler, Chris Andrews, Laurie A Ford, et al.
Clinical Therapeutics|October 9, 2017
Enrollment of Neonates in More Than One Clinical TrialJonathan M Davis, Gerri R Baer, Ronald Portman, et al.
Annals of Hematology|September 22, 2011
Is obesity a prognostic factor for acute myeloid leukemia outcome?Hun Ju Lee, Andrea S Licht, Andrew J Hyland, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2021
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimensSarah M Kashanian, Noa G Holtzman, Ciera L Patzke, et al.
Pageof 63

Showing results (431-440 of 628) with videos related to

Sort By:
Pageof 63
Proceedings of the ... IEEE Conference on Nanotechnology. IEEE Conference on Nanotechnology|June 21, 2014
Testing in EHS: What is the Current Status of Experimentation?Donald R Baer, Ajay S Karakoti, Prabhakaran Munusamy, et al.
Leukemia & Lymphoma|July 25, 2014
A novel TTC40-MSI2 fusion in de novo acute myeloid leukemia with an unbalanced 10;17 translocationReza Saleki, Todd Christensen, Weihua Liu, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Leukemia Research|July 20, 2018
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasmsJ Berdeja, F Palandri, M R Baer, et al.
Nature Genetics|December 1, 1996
Identification of a RING protein that can interact in vivo with the BRCA1 gene productL C Wu, Z W Wang, J T Tsan, et al.
International Journal of Molecular Epidemiology and Genetics|September 28, 2011
XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemiaNataliya Kuptsova-Clarkson, Christine B Ambrosone, Joli Weiss, et al.
Cancer|April 2, 2011
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaMeir Wetzler, Chris Andrews, Laurie A Ford, et al.
Clinical Therapeutics|October 9, 2017
Enrollment of Neonates in More Than One Clinical TrialJonathan M Davis, Gerri R Baer, Ronald Portman, et al.
Annals of Hematology|September 22, 2011
Is obesity a prognostic factor for acute myeloid leukemia outcome?Hun Ju Lee, Andrea S Licht, Andrew J Hyland, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2021
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimensSarah M Kashanian, Noa G Holtzman, Ciera L Patzke, et al.
Pageof 63